CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL CANCER OF THE LUNG - REPORT OF A CLINICAL-TRIAL AND REVIEW OF THE LITERATURE

被引:10
作者
BRENEMAN, JC [1 ]
MITCHELL, SE [1 ]
HAWLEY, DK [1 ]
ARON, BS [1 ]
SCHRODER, LE [1 ]
机构
[1] UNIV CINCINNATI, MED CTR, BARRETT CANC CTR, DIV HEMATOL ONCOL, CINCINNATI, OH 45267 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1991年 / 14卷 / 01期
关键词
LUNG CANCER; NON-SMALL-CELL; RADIATION; CHEMOTHERAPY;
D O I
10.1097/00000421-199102000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A prospective nonrandomized phase II study was begun in 1985 using concurrent split-course radiation and chemotherapy in the treatment of locally advanced non-small-cell cancer of the lung. Patients were treated with 3,000 cGy of radiation in 15 fractions to the chest, together with 100 mg/m2 cisplatin on day 1 and 1,000 mg/m2/day 5-fluorouracil infusion on days 1-4. The radiation and chemotherapy were then repeated after a 1-week break. Twenty-one patients were treated, with five patients having a complete response and nine patients having a partial response for an overall response rate of 67%. With a minimum of 24 months follow-up, five patients remain alive. Median survival for the entire group is 11.6 months. The toxicity of the treatment regimen was acceptable. These results do not differ significantly from survivals of similar patients treated with radiation alone, including a series from our own institution. The literature on concurrent chemotherapy and radiation is reviewed and possible future approaches to this tumor are discussed.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 36 条
  • [1] ALLAIRE FJ, 1961, CANCER CHEMOTH REP, P59
  • [2] THERAPEUTIC ENHANCEMENT IN MICE BY CLINICALLY RELEVANT DOSE AND FRACTIONATION SCHEDULES OF CIS-DIAMMINEDICHLOROPLATINUM(II) AND IRRADIATION
    BARTELINK, H
    KALLMAN, RF
    RAPACCHIETTA, D
    HART, GAM
    [J]. RADIOTHERAPY AND ONCOLOGY, 1986, 6 (01) : 61 - 74
  • [3] BONOMI P, 1988, NATL CANCER I MONOGR, V6, P331
  • [4] BYFIELD JE, 1983, CANCER TREAT REP, V67, P933
  • [5] CALDWELL WL, 1968, CANCER, V22, P999, DOI 10.1002/1097-0142(196811)22:5<999::AID-CNCR2820220515>3.0.CO
  • [6] 2-D
  • [7] CARR DT, 1972, CANCER, V29, P375, DOI 10.1002/1097-0142(197202)29:2<375::AID-CNCR2820290218>3.0.CO
  • [8] 2-H
  • [9] COUGHLIN CT, 1986, CANCER TREAT REP, V70, P643
  • [10] COY P, 1970, CANCER, V26, P803, DOI 10.1002/1097-0142(197010)26:4<803::AID-CNCR2820260410>3.0.CO